Laser Surgery Care — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$82,834	2
2024	Research	$86,946	2
2023	Research	$149,765	3
2022	Research	$34,547	2
2021	Research	$110,392	4
2020	Research	$75,610	28

Breakdown

Who paid Research payments · program years 2020–2025

Merck Sharp & Dohme Corporation $482,762 39 payments
Covidien LP $46,481 1 payment
Medtronic, Inc. $10,850 1 payment

Studies the money was for Research payments · program years 2020–2025

V503-049 A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age $394,334 15 payments
A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent $63,683 1 payment
Investigator Sponsored Research $57,331 2 payments
A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent $19,150 1 payment
V503-049 A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age $4,689 16 payments
V503-049 A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age $763 3 payments
A Study to Evaluate the Efficacy of GARDASILTM in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related External Genital Warts, PIN, Penile, Perianal, and Perineal Cancer, and the Incidence of HPV 6-, 11-, 16-, and 18-Related Genital Infection in Young Men $141 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.